Agenus shares surge 11.21% intraday after reporting Q3 clinical advances and France regulatory approvals.

Agenus Inc. surged 11.21% intraday following the release of Q3 2025 results highlighting clinical and regulatory advancements. The company announced reimbursed compassionate access for its botensilimab/balstilimab (BOT/BAL) combination in France for refractory metastatic colorectal cancer, marking the first government-funded access for this patient population. Updated clinical data showed 42% two-year survival in MSS mCRC patients and 39% across multiple cancers, reinforcing BOT/BAL’s potential. Additionally, the global Phase 3 BATTMAN trial is set to launch in Q4 2025, signaling regulatory progress. Financially, a $100.9 million gain from the deconsolidation of MiNK Therapeutics and a $10 million bridge facility with Zydus contributed to a $63.9 million net income, contrasting with prior losses. These developments, emphasizing therapeutic efficacy, expanded access, and financial improvement, drove the intraday rally.